179605-63-1

Basic information

• Product Name: (S)-OCTAHYDRO-PYRIDO[1,2-A]PYRAZINE
• Synonyms: 2H-Pyrido[1,2-a]pyrazine, octahydro-, (9aS)-;(S)-OCTAHYDRO-PYRIDO[1,2-A]PYRAZINE;(9aS)-Octahydro-2H-pyrido[1,2-a]pyrazine 2HCl;(9aS)-Octahydro-2H-pyrido[1,2-a]pyrazine
• CAS NO: 179605-63-1
• Molecular Formula: C₈H₁₆N₂
• Molecular Weight: 140.228
• Mol File: 179605-63-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-OCTAHYDRO-PYRIDO[1,2-A]PYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-OCTAHYDRO-PYRIDO[1,2-A]PYRAZINE(179605-63-1)
• EPA Substance Registry System: (S)-OCTAHYDRO-PYRIDO[1,2-A]PYRAZINE(179605-63-1)

Safety Data

• Hazardous Substances Data: 179605-63-1(Hazardous Substances Data)

Usage

Uses

Used in the Food Industry:
(S)-OCTAHYDRO-PYRIDO[1,2-A]PYRAZINE is used as a flavoring agent for its nutty and roasted aroma, particularly enhancing the taste of coffee and cocoa products. It also serves to improve the aroma of various other foods and beverages, including meat, dairy, and baked goods.
Used in the Pharmaceutical Industry:
(S)-OCTAHYDRO-PYRIDO[1,2-A]PYRAZINE is studied for its potential pharmacological effects, such as anti-inflammatory and antioxidant properties. While further research is necessary to fully comprehend its biological activities, this chemical shows promise for various pharmaceutical applications.

Upstream product

• 153918-98-0 (2R)-2-<(2S)-2-(aminomethyl)piperidin-1-yl>-2-phenylethanol 
• 248914-28-5 (S)-4-oxooctahydro-2H-pyrido[1,2-a]pyrazine 
• 101392-99-8 (S)-hexahydro-1H-pyridine [1,2-a]pyrazine-1,4(6H)-dione 
• 139004-93-6 (S)-tert-butyl (piperidin-2-ylmethyl)carbamate 
• 248914-23-0 tert-butyl ({(2S)-1-[(1R)-2-hydroxy-1-phenylethyl]piperidin-2-yl}methyl)carbamate 
• 248914-24-1 tert-butyl {[(2S)-1-(chloroacetyl)piperidin-2-yl]methyl}carbamate 
• 248914-26-3 (S)-2-tert-butoxycarbonyl-4-oxooctahydro-2H-pyrido[1,2-a]pyrazine 

Downstream Products

• 639069-00-4 C₂₅H₃₅N₃O₂ 

Relevant articles and documents

Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists

Bicyclic piperazine derivatives were synthesized as conformationally constrained analogs of N-alkyl piperazines and were found to be potent CB1 receptor agonists. The CB1 receptor agonist activity was dependent upon the absolute configuration of the chiral center of the bicyclic ring system. Although the conformational constraint did not protect the compounds from metabolism by N-dealkylation, several bicyclic analogs were found to be more potent than the unconstrained lead compound. Compound 8b demonstrated potent antinociceptive activity in vivo.

TRICYCLIC 1-[(3-INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS

The invention relates to tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula (I) wherein X is CH2, O or S; R represents 1-3 substituents independently selected from H, (C1-4)alkyl, (C1-4)alky

Asymmetric synthesis of octahydro-2H-pyrido[1,2-a]-pyrazines

A series of optically pure octahydro-2H-pyrido[1,2-a]pyrazines has been prepared from (-)-2-cyano-6-phenyloxazolopiperidine (4). 2H-Pyrido[1,2- a]pyrazin-3-(4H)-one (7) and octahydro-2H-pyrido[1,2-a]pyrazine (14) were obtained from diamino alcohol (5) by

BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY

Described herein are D4 receptor-selective compounds of the general formula: STR1 wherein: A and B are independently selected, substituted or unsubstituted, unsaturated 5-or 6-membered, homo-or heterocyclic rings;X 1 is selected from O, S, SO, SO 2, CH. sub.2, C=O, CH--OH, CH--N(C 1-4 alkyl) 2, C= CHCl, and C=CHCN;X 2---is selected from N= , CH. sub.2--, CH= and C(O)--;n is 1 or 2; R 1 is selected from H and the α-carbon side chain of an amino acid;R 2 and R 3 are selected independently from H, OH,--NH 2,--C(O)NH 2 =O, =S,halo, cyano, C 1-9 alkyl, C 1-9 alkoxy, C 1-4 alkylS--, C 1-4 alkylSO--, C 1-4 alkylSO 2--, phenoxy, benzyloxy and piperonyloxy; andH* is in either the R-or the S-configuration,and acid addition salts, solvates and hydrates thereof.Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.